Keywords: Alnylam, Genzyme, Sanofi, RNAi therapeutics, ATTR, Japan, Asia-Pacific

Alnylam gets upfront $22.5 million in RNAi link with Genzyme

Article | 23 October 2012

Print This

French drug major Sanofi’s (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive alliance with the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in